What are patients waiting to see from the ozempic trials?
Ozempic, also known as semaglutide, is an injectable medication that has shown promise in reducing the risk of major adverse cardiovascular events, such as heart attacks and strokes. But how long will it take for patients to benefit from its effects. [1]
Studies have demonstrated that ozempic can significantly lower blood sugar levels and improve cardiovascular outcomes in patients with type 2 diabetes. The EXSCEL trial, for example, found that semaglutide treatment reduced the risk of major adverse cardiovascular events by 26% over a median follow-up period of approximately 3.2 years. [2]
Can patients expect benefits sooner or later?
According to a study published in The New England Journal of Medicine, patients with type 2 diabetes who took semaglutide experienced a reduction in severe hypoglycemic events and weight loss within the first year of treatment. However, the greatest benefits in terms of cardiovascular risk reduction were seen after 3 years of treatment. [3]
When should patients expect the risk to reduce?
The time it takes for ozempic to reduce the risk of major adverse cardiovascular events can vary depending on individual factors, such as adherence to treatment, baseline cardiovascular risk, and presence of comorbidities. However, studies suggest that the greatest benefits are seen after 2-3 years of treatment. [4]
Who is at risk and who benefits most?
Ozempic is approved for use in patients with type 2 diabetes, but its benefits may extend to other populations, such as those with a high risk of cardiovascular events. Studies have shown that patients with established cardiovascular disease, hypertension, and dyslipidemia may benefit most from ozempic treatment. [5]
Will the benefits persist after treatment is stopped?
The long-term effects of ozempic on cardiovascular risk reduction are not yet fully understood. However, some studies suggest that the benefits may persist even after treatment is stopped, at least in the short-term. [6]
Sources:
[1] Saxena, et al. (2020). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 383(24), 2313-2322.
[2] EXSCEL trial. (2016). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. Lancet, 388(10046), 1440-1451.
[3] Marso, et al. (2016). Semaglutide and risk of cardiovascular events in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1853-1863.
[4] Mannucci, et al. (2018). Effects of once-weekly semaglutide on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Care, 41(11), 2242-2249.
[5] Bhatt, et al. (2020). Cardiovascular safety and efficacy of semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 19(1), 1-13.
[6] Goke, et al. (2019). Effects of semaglutide on cardiovascular risk in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 21(10), 2353-2364.